Pharmaceuticals

Wolwo Pharma

Wolwo Pharma released FY2025 earnings on April 23 After-Market (BJT), actual revenue CNY 1.062 B (forecast CNY 1.081 B), actual EPS CNY 0.7276 (forecast CNY 0.77)

Wolwo Pharma released FY2026 Q1 earnings on April 23 Pre-Market (BJT), actual revenue CNY 252.84 M, actual EPS CNY 0.2277

Wolwo Pharma released FY2025 Q4 earnings on April 23 After-Market (BJT), actual revenue CNY 209.04 M, actual EPS CNY 0.0689

Wolwo Pharma to Release FY2025 Earnings on April 24 After-Market (BJT), Forecast Revenue CNY 1.081 B, EPS CNY 0.77

Wolwo Pharma to Release FY2026 Q1 Earnings on April 24 Pre-Market BJT

Wolwo Pharma released FY2025 9 Months earnings on October 23 During-Market (BJT), actual revenue CNY 853.36 M, actual EPS CNY 0.6586

Wolwo Pharma released FY2025 Q3 earnings on October 23 During-Market (BJT), actual revenue CNY 369.12 M, actual EPS CNY 0.3205

Wolwo Pharma to Release FY2025 Q3 Earnings Report on October 24 During-Market (BJT)

Wolwo Pharma released FY2025 Semi-Annual earnings on August 21 After-Market (BJT), actual revenue CNY 484.24 M, actual EPS CNY 0.3381

Wolwo Pharma released FY2025 Q2 earnings on August 21 After-Market (BJT), actual revenue CNY 255.76 M, actual EPS CNY 0.196

Wolwo Pharma to Release FY2025 Semi-Annual Earnings on August 22, 2025 (BJT)

I-Med Biologics Initiates Phase I Clinical Study for Dermatitis Diagnostic Patch 02

I WU Biopharma's Cocklebur Pollen Sublingual Droplet Clinical Trial Results Positive

I Wubo Releases Q2 2025 Earnings Guidance

I WU Bio releases 2025 H1 Earnings Forecast

My Wu Bio Director and Executives Sell Shares

Iwubiotech Responds to Stem Cell Drug R&D Progress and Policy Utilization Plan

iWu Biologics Responds to Stem Cell Research and Medical Insurance Negotiations

Zhongtai Securities Maintains Overweight Rating for Ivy Biopharma

I-Mab denies stem cell research clinical application rumors this year

300357

According to the Zhitong Finance APP, Wolwo Pharma released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 853 million yuan, a year-on-year increase of 16.86%. The net profit attributable to shareholders of the listed company was 345 million yuan, a year-on-year increase of 26.67%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 340 million yuan, a year-on-year increase of 28.92%. The basic earnings per share were 0.6587 yuan

Zhitong

Wolwo Pharma released its performance for the first three quarters, with a net profit attributable to the parent company of 345 million yuan, an increase of 26.67%

300255

688131

300497

688202

A-share innovative drug concept stocks fluctuated and rose, Wolwo Pharma increased by over 10%, Chemexpress rose by over 9%, Fushine, CSBIO, and Medicilon followed suit

CSBIO

Chemexpress

Fushine

Medicilon

Wolwo Pharma has completed the Phase I clinical trial of the Aspergillus flavus puncture solution and obtained the summary report. The study shows that the drug has good safety within the set dosage range, with no serious adverse reactions occurring. Some subjects experienced delayed reactions, which may be related to the characteristics of the fungus. The specificity for each dosage exceeded 95%, and the sensitivity reached 95% at 55000 DU/mL. The researchers recommend conducting subsequent clinical studies at doses of 55000 DU/mL and above, and exploring strategies to reduce delayed reactions

Wolwo Pharma obtained the summary report of Phase I clinical trial for Aspergillus flavus puncture solution

Wolwo Pharma announced that it has completed the clinical trial of the "Artemisia Annua Pollen Allergen Sublingual Drops." The summary report indicates that the product has good safety in adult patients with allergic rhinitis, with the main adverse reactions being grade 1 and 2. After 2 years of treatment and monitoring after discontinuation, it has been confirmed that the drug effectively improves symptoms caused by Artemisia Annua/Artemisia Pollen and reduces the use of symptomatic medications, providing evidence for long-term clinical application

Wolwo Pharma obtained the clinical trial summary report for the sublingual drops of Artemisia annua pollen allergen after its market launch

Zhongtai Securities maintains a "Buy" rating for Wolwo Pharma, expecting a net profit attributable to the parent company of 318 million yuan in 2024, a year-on-year increase of 2.46%. The net profit attributable to the parent company for the first quarter of 2025 is expected to be 74 million yuan, a year-on-year decrease of 3.71%. The company's revenue growth is steady, core products continue to increase in volume, market share exceeds 80%, and the sales of Artemisia annua powder drops continue to grow, with the product line constantly expanding

ZHONGTAI SECURITIES

Zhongtai Securities: Maintain Wolwo Pharma "Buy" rating, steady revenue growth, core products continue to expand

688266

300347

03347

Multiple innovative drug concept stocks have gained favor from the social security fund. Statistics show that in this year's first quarterly report, a total of 15 stocks were heavily held by the social security fund, with a combined market value of holdings reaching 4.102 billion yuan, of which 6 stocks were newly added in the first quarter. Wolwo Pharma, Tigermed, and Zelgen ranked highest in market value held by the social security fund, at 555 million yuan, 488 million yuan, and 475 million yuan, respectively

Zelgen

Tigermed

TIGERMED

At the end of the first quarter, the social security fund held multiple innovative drug concept stocks

Wolwo Pharma has received approval from the National Medical Products Administration to conduct clinical trials for the "Dermatitis Diagnostic Patch 02." This product is used to assist in the diagnosis of allergic contact dermatitis related to carbamazepine, p-phenylenediamine, and formaldehyde, further expanding the company's product development pipeline in the field of allergic disease diagnosis

Wolwo Pharma has obtained clinical trial approval for the dermatitis diagnostic patch 02

According to the Zhitong Finance APP, Wolwo Pharma released its first quarter report for 2025, with operating revenue of 228 million yuan, a year-on-year increase of 5.65%. The net profit attributable to shareholders of the listed company was 74.3421 million yuan, a year-on-year decrease of 3.71%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 73.6184 million yuan, a year-on-year increase of 1.48%. The basic earnings per share were 0.142 yuan

Wolwo Pharma released its first-quarter performance, with a net profit attributable to the parent company of 74.3421 million yuan, a decrease of 3.71%

Wolwo Pharma released its 2024 annual report, with operating revenue of 925 million yuan, a year-on-year increase of 9.10%; net profit attributable to the parent company of 318 million yuan, a year-on-year increase of 2.46%; and net profit excluding non-recurring gains and losses of 306 million yuan, a year-on-year increase of 2.72%. The basic earnings per share are 0.607 yuan, and it plans to distribute a cash dividend of 1.20 yuan (tax included) for every 10 shares to all shareholders

Wolwo Pharma released its 2024 annual performance, with a net profit attributable to the parent company of 318 million yuan, an increase of 2.46%

According to the Zhitong Finance APP, Wolwo Pharma announced that the "house dust mite film agent" developed by the company has completed the enrollment of the first subject in the "Clinical Study on the Safety and Tolerability of Sublingual Administration of 'House Dust Mite Film Agent' in Chinese Adults with Dust Mite Allergic Rhinitis" at Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, officially entering this clinical trial

Wolwo Pharma: The first subject has been enrolled in the Phase I clinical trial of the house dust mite membrane agent

Wolwo Pharma(300357.SZ)